The COVID-19 vaccine moved the markets once again - Monday Review, December 14

By: Miguel A. Rodriguez

11:13, 15 December 2020

1608023557.jpg
Markets were mostly high on COVID-19 vaccine approval

The US

The prospects of new restrictions to curb the spread of COVID-19 infections caused most of the benchmarks to close in the red. USA30 fell 0.62%, while USA500 dropped 0.49%. TECH100 jumped 0.50%.

Crude oil closed the session at $47.15 a barrel after it gained 1.3%.

Gold fell 0.7% to $1,830.25 per ounce.

 

Asia and Australia

In part, investors were cheered by Pfizer's COVID-19 vaccine's latest approval by the US Food and Drug Administration.

Japan225 rose 0.59%.

HongKong45 lost 0.04% after some major companies like Alibaba, Tencent-backed China Literature, and Hive Box Technology got fines from its market regulator.

Down under, Australia200 gained 0.51% as the market expects the minutes from the Reserve Bank of Australia's latest policy meeting.

 

Europe

The Brexit negotiations were extended past the Sunday deadline, which led the markets to trade higher. The UK's Prime Minister Boris Johnson and EC President Ursula von der Leyen continue to negotiate a trade deal.

Germany30 and France40 each closed 0.8% higher. UK100 added 0.1%.

Brent oil closed 1.2% higher at $50.55 per barrel.

EUR/USD traded at 1.2144 after it went up 0.3%.

Sources: investing.com, reuters.com

Share this article

The information presented herein is prepared by CAPEX.com/eu and does not intend to constitute Investment Advice. The information herein is provided as a general marketing communication for information purposes only and as such it has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and it is not subject to any prohibition on dealing ahead of the dissemination of investment research.                                                                                                                            Users/readers should not rely solely on the information presented herewith and should do their own research/analysis by also reading the actual underlying research. The content herewith is generic and does not take into consideration individual personal circumstances, investment experience, or current financial situation.Therefore, Key Way Investments Ltd shall not accept any responsibility for any losses of traders due to the use and the content of the information presented herein. Past performance and forecasts are not reliable indicators of future results.